<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Cancer-associated thrombosis (CAT) is a major cause of death in oncological patients. The mechanisms of thrombogenesis in cancer patients are not fully established, and it seems to be multifactorial in origin. Also, several risk factors for venous thromboembolism (VTE) are present in these patients such as tumor site, stage, histology of cancer, chemotherapy, surgery, and immobilization. Anticoagulant treatment in CAT is challenging because of high bleeding risk during treatment and recurrence of VTE. Current major guidelines recommend low molecular weight heparins (LMWHs) for early and long-term treatment of VTE in cancer patients. In the past years, direct oral anticoagulants (DOACs) are recommended as potential treatment option for VTE and have recently been proposed as a new option for treating CAT. This manuscript will give a short overview of risk factors involved in the development of CAT and a summary on the recent recommendations and guidelines for treatment of VTE in patients with malignancies, discussing also some special clinical situations (e.g. renal impairment, catheter-related thrombosis, and thrombocytopenia).</p>
</abstract>

Cancer-associated thrombosis (CAT) is a major cause of death in oncological patients. The mechanisms of thrombogenesis in cancer patients are not fully established, and it seems to be multifactorial in origin. Also, several risk factors for venous thromboembolism (VTE) are present in these patients such as tumor site, stage, histology of cancer, chemotherapy, surgery, and immobilization. Anticoagulant treatment in CAT is challenging because of high bleeding risk during treatment and recurrence of VTE. Current major guidelines recommend low molecular weight heparins (LMWHs) for early and long-term treatment of VTE in cancer patients. In the past years, direct oral anticoagulants (DOACs) are recommended as potential treatment option for VTE and have recently been proposed as a new option for treating CAT. This manuscript will give a short overview of risk factors involved in the development of CAT and a summary on the recent recommendations and guidelines for treatment of VTE in patients with malignancies, discussing also some special clinical situations (e.g. renal impairment, catheter-related thrombosis, and thrombocytopenia).

Current Recommendations for the Management of Cancer-Associated Venous Thromboembolism

“George Emil Palade” University of Medicine, Pharmacy, Science and Technology

Journal of Cardiovascular Emergencies

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Cancer-associated thrombosis (CAT) is a major cause of death in oncological patients. The mechanisms of thrombogenesis in cancer patients are not fully...

Current Recommendations for the Management of Cancer-Associated Venous Thromboembolism

Data publikacji: 17 lip 2021

Zakres stron: 27 - 38

Otrzymano: 07 lut 2021

Przyjęty: 15 kwi 2021

DOI: https://doi.org/10.2478/jce-2021-0009

Słowa kluczowe
cancer-associated thrombosis, low molecular weight heparins, direct oral anticoagulants

© 2021 Katalin Makó, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Current Recommendations for the Management of Cancer-Associated Venous Thromboembolism

Data publikacji: 17 lip 2021

Zakres stron: 27 - 38

Otrzymano: 07 lut 2021

Przyjęty: 15 kwi 2021

DOI: https://doi.org/10.2478/jce-2021-0009

Słowa kluczowecancer-associated thrombosis, low molecular weight heparins, direct oral anticoagulants

© 2021 Katalin Makó, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Słowa kluczowe
cancer-associated thrombosis, low molecular weight heparins, direct oral anticoagulants